NADAC acquisition cost data for HUMALOG MIX 75-25 KWIKPEN. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00002879759 | $33.92 | 2022-05-18 | Rx |
| 00002879759 | $33.92 | 2022-05-18 | Rx |
| 00002879759 | $33.92 | 2022-05-18 | Rx |
| 00002879759 | $33.92 | 2022-05-18 | Rx |
| 00002879759 | $33.92 | 2022-05-18 | Rx |
| 00002879759 | $33.92 | 2022-05-18 | Rx |
| 00002879759 | $33.92 | 2022-05-18 | Rx |
| 00002879759 | $33.92 | 2022-05-18 | Rx |
| 00002879759 | $33.92 | 2022-05-18 | Rx |
| 00002879759 | $33.92 | 2022-05-18 | Rx |
Generic: Insulin Lispro | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $549.2M | 1,053,989 | 246,647 | $26.55 |
| 2020 | $449.3M | 759,810 | 192,852 | $26.05 |
| 2021 | $435.1M | 647,732 | 167,509 | $26.76 |
| 2022 | $440.8M | 599,935 | 157,502 | $26.99 |
| 2023 | $458.1M | 572,082 | 156,031 | $26.87 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| Puerto Rico | $37.1M | 69,989 | 12,940 |
| California | $36.5M | 60,416 | 18,639 |
| Texas | $28.9M | 32,025 | 10,740 |
| Florida | $27.3M | 28,741 | 9,105 |
| Ohio | $19.5M | 22,438 | 6,664 |
| New York | $19.5M | 22,180 | 6,222 |
| Pennsylvania | $19.3M | 24,696 | 6,182 |
| Illinois | $18.1M | 21,812 | 6,019 |
| Michigan | $16.0M | 17,950 | 5,623 |
| Tennessee | $14.8M | 14,436 | 4,251 |
| Georgia | $14.8M | 16,460 | 4,749 |
| North Carolina | $14.6M | 15,465 | 4,463 |
| New Jersey | $14.0M | 18,519 | 4,795 |
| Indiana | $12.4M | 14,625 | 3,964 |
| Arizona | $11.6M | 12,726 | 4,114 |
| Virginia | $11.3M | 13,584 | 4,134 |
| Massachusetts | $10.8M | 14,895 | 4,168 |
| Missouri | $10.3M | 10,329 | 2,981 |
| Washington | $9.8M | 11,567 | 3,555 |
| Alabama | $8.8M | 10,367 | 2,734 |
| Kentucky | $8.3M | 8,818 | 2,430 |
| Wisconsin | $8.0M | 7,579 | 2,077 |
| Colorado | $6.4M | 7,944 | 2,472 |
| Connecticut | $6.3M | 7,657 | 2,070 |
| South Carolina | $6.0M | 6,215 | 1,875 |
| Minnesota | $5.7M | 5,379 | 1,625 |
| Oregon | $5.6M | 6,829 | 2,115 |
| Maryland | $5.3M | 7,232 | 2,241 |
| Iowa | $4.5M | 5,834 | 1,413 |
| Louisiana | $4.4M | 6,102 | 1,647 |
| Arkansas | $4.3M | 6,142 | 1,666 |
| Oklahoma | $3.8M | 4,761 | 1,350 |
| Utah | $3.6M | 3,171 | 980 |
| Kansas | $2.9M | 3,285 | 821 |
| Nebraska | $2.8M | 3,294 | 811 |
| New Hampshire | $2.6M | 2,494 | 763 |
| West Virginia | $2.3M | 3,097 | 854 |
| Mississippi | $2.3M | 3,126 | 950 |
| New Mexico | $2.2M | 2,521 | 725 |
| Nevada | $2.2M | 2,359 | 787 |
| Maine | $2.2M | 2,443 | 704 |
| Idaho | $2.1M | 2,275 | 631 |
| Rhode Island | $1.8M | 2,496 | 677 |
| Montana | $1.1M | 1,160 | 323 |
| Delaware | $981.2K | 915 | 290 |
| South Dakota | $884.0K | 838 | 233 |
| Vermont | $808.3K | 816 | 226 |
| North Dakota | $682.6K | 747 | 183 |
| Alaska | $556.9K | 506 | 161 |
| District of Columbia | $528.7K | 821 | 253 |
| Hawaii | $460.0K | 928 | 279 |
| Wyoming | $373.9K | 523 | 147 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.